Wall Street analysts expect Denali Therapeutics Inc (NASDAQ:DNLI) to announce $4.52 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Denali Therapeutics’ earnings, with the lowest sales estimate coming in at $1.65 million and the highest estimate coming in at $8.40 million. Denali Therapeutics posted sales of $1.65 million in the same quarter last year, which suggests a positive year-over-year growth rate of 173.9%. The firm is expected to issue its next earnings results on Thursday, August 8th.
On average, analysts expect that Denali Therapeutics will report full-year sales of $64.30 million for the current financial year, with estimates ranging from $16.46 million to $132.72 million. For the next year, analysts forecast that the business will report sales of $168.43 million, with estimates ranging from $16.00 million to $350.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%.
Shares of DNLI stock traded up $0.13 during trading hours on Friday, reaching $20.73. 266,881 shares of the company’s stock were exchanged, compared to its average volume of 390,055. Denali Therapeutics has a 1 year low of $12.32 and a 1 year high of $28.86. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -53.15 and a beta of 2.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.55 and a current ratio of 11.55.
In related news, COO Alexander O. Schuth sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $22.58, for a total value of $169,350.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ryan J. Watts sold 18,334 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $24.20, for a total value of $443,682.80. The disclosure for this sale can be found here. Insiders have sold 96,000 shares of company stock worth $2,279,169 in the last 90 days. Insiders own 21.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Baillie Gifford & Co. boosted its position in Denali Therapeutics by 0.6% in the first quarter. Baillie Gifford & Co. now owns 6,262,226 shares of the company’s stock valued at $145,408,000 after buying an additional 34,502 shares during the last quarter. Vanguard Group Inc. boosted its position in Denali Therapeutics by 52.5% in the third quarter. Vanguard Group Inc. now owns 4,827,710 shares of the company’s stock valued at $104,954,000 after buying an additional 1,660,984 shares during the last quarter. BlackRock Inc. boosted its position in Denali Therapeutics by 38.3% in the fourth quarter. BlackRock Inc. now owns 4,572,695 shares of the company’s stock valued at $94,469,000 after buying an additional 1,265,645 shares during the last quarter. Lord Abbett & CO. LLC boosted its position in Denali Therapeutics by 27.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,438,608 shares of the company’s stock valued at $29,722,000 after buying an additional 313,153 shares during the last quarter. Finally, Wasatch Advisors Inc. boosted its position in Denali Therapeutics by 1,702.4% in the first quarter. Wasatch Advisors Inc. now owns 820,904 shares of the company’s stock valued at $19,061,000 after buying an additional 775,358 shares during the last quarter. Hedge funds and other institutional investors own 71.23% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
See Also: Golden Cross
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.